Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Tyme Technologies Inc    TYME

 SummaryQuotesChartsNewsCompany 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/18/2017 09/19/2017 09/20/2017 09/21/2017 09/22/2017 Date
6.2(c) 5.7(c) 5.5(c) 5.4(c) 5.32(c) Last
145 711 104 833 157 399 19 561 37 742 Volume
-0.16% -8.06% -3.51% -1.82% -1.48% Change
More quotes
Company
Tyme Technologies, Inc. is a clinical-stage biopharmaceutical company focused on development and commercialization of highly targeted cancer therapeutics with a broad range of oncology indications.Its lead investigational candidate, SM-88, is a novel first-in-class therapy that is designed to use... 
Sector
Biotechnology & Medical Research
Calendar

- No events available -

More about the company
Latest news on TYME TECHNOLOGIES INC
09/14 Tyme Adds Distinguished Drug Developer, Briggs W. Morrison, M.D. to Advisory ..
09/13 TYME TECHNOLOGIES : Presentation at ESMO Reported 100% of Current Prostate Cance..
09/11 TYME TECHNOLOGIES : Updated Long Term Analysis Shows 29 Month Median Overall Sur..
09/11 TYME TECHNOLOGIES, INC. : Other Events, Financial Statements and Exhibits (form ..
09/11 TYME TECHNOLOGIES, INC. : Regulation FD Disclosure, Financial Statements and Exh..
09/11 TYME Presentation at ESMO Reported 100% of Current Prostate Cancer Patients H..
09/07 TYME TECHNOLOGIES, INC. : Other Events, Financial Statements and Exhibits (form ..
09/07 Tyme’s Updated Long-Term Analysis Shows 29-Month Median Overall Surviva..
08/31 TYME TECHNOLOGIES : to Present at Upcoming Investor Conferences
08/30 TYME TECHNOLOGIES : Inc. to Present Prostate Cancer Data from its Ongoing Phase ..
More news
Sector news : Bio Therapeutic Drugs
09/20DJSANOFI : Alnylam Report Positive Patisiran Phase III Trial, First-Ever for RNAi ..
09/15 Drug industry on tenterhooks as Maryland price-gouging law nears
09/07 New AstraZeneca, Amgen drug looks strong rival in severe asthma
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag -- Update
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag
More sector news : Bio Therapeutic Drugs
Chart TYME TECHNOLOGIES INC
Duration : Period :
Tyme Technologies Inc Technical Analysis Chart | TYME | US90238J1034 | 4-Traders
Managers
NameTitle
Steve Hoffman Chief Executive Officer & Director
Ben Taylor President & Chief Financial Officer
Michael Demurjian Chief Operating Officer, Director & Executive VP
Guiseppe Del Priore Chief Medical Officer
Jonathan M. Eckard Chief Scientific Affairs Officer
Sector and Competitors
1st jan.Capitalization (M$)
TYME TECHNOLOGIES INC46.67%475
AMGEN28.70%135 544
CELGENE CORPORATION24.61%112 572
GILEAD SCIENCES15.40%108 744
REGENERON PHARMACEUTICALS19.36%46 367
VERTEX PHARMACEUTICALS107.30%38 136